Preoperative Clearance for 65-Year-Old on GLP-1 Before Knee Replacement
Continue the GLP-1 receptor agonist through surgery with full aspiration risk assessment and mitigation strategies, obtain HbA1c if not done in the last 3 months, and proceed with standard preoperative cardiovascular evaluation without additional testing beyond what would be required for any healthy 65-year-old undergoing elective total knee arthroplasty 1, 2.
GLP-1 Management Strategy
The most recent 2025 multidisciplinary UK consensus statement provides clear guidance: patients taking GLP-1 receptor agonists should continue these medications before surgery rather than discontinuing them 1. This represents a significant shift from earlier recommendations and is based on:
- Full risk assessment and stratification for aspiration
- Implementation of peri-operative techniques to mitigate pulmonary aspiration risk
- Shared decision-making approach with the patient
Key Aspiration Risk Assessment
Evaluate for high-risk features that would warrant additional precautions 3:
- Recent initiation of GLP-1 therapy (within weeks)
- Recent dose escalation
- Active gastrointestinal symptoms (nausea, vomiting, bloating, early satiety)
- Non-fasting status
If the patient is asymptomatic on a stable dose, aspiration risk is not significantly elevated and the medication can be continued 3. The anesthesia team should still employ aspiration mitigation strategies (rapid sequence induction, cricoid pressure consideration, or point-of-care gastric ultrasound if available).
Required Preoperative Testing
Glycemic Control Assessment
Obtain HbA1c if not checked within the last 3 months 2. This is reasonable for risk stratification, though there is no validated threshold that mandates surgery postponement. If HbA1c exceeds 8%, consider discussing optimization with the patient, but do not delay elective surgery solely for this reason as there is no evidence that deferral improves cardiovascular outcomes 2.
Standard Cardiovascular Evaluation
For an otherwise healthy 65-year-old undergoing elective total knee arthroplasty:
- No additional cardiac testing is required beyond standard preoperative assessment 2
- Basic metabolic panel and complete blood count are reasonable
- ECG is appropriate given age >65 years
- No routine stress testing or echocardiography unless symptomatic or meeting other high-risk criteria per ACC/AHA guidelines
Anesthesia Considerations
Either neuraxial or general anesthesia is reasonable with no apparent difference in cardiovascular outcomes 2. The choice should be made collaboratively with anesthesia, considering:
- Patient preference
- Aspiration risk mitigation (may favor neuraxial if concerns exist)
- Surgical factors
If general anesthesia is chosen, both volatile-based agents and total intravenous anesthesia are reasonable with equivalent cardiovascular safety profiles 2.
Critical Pitfalls to Avoid
Do NOT Discontinue GLP-1 Perioperatively
The 2025 consensus explicitly recommends continuation 1, contradicting older guidance. Stopping these medications unnecessarily may worsen glycemic control and eliminate cardiovascular benefits without meaningfully reducing aspiration risk in stable, asymptomatic patients.
Do NOT Confuse with SGLT2 Inhibitors
If the patient were on an SGLT2 inhibitor (which they are not in this scenario), that medication must be stopped 3-4 days before surgery to prevent euglycemic diabetic ketoacidosis 2. GLP-1 agonists do not carry this risk.
Do NOT Delay Surgery for HbA1c Optimization
While checking HbA1c is reasonable, emergent or time-sensitive procedures should never be delayed to achieve target levels 2. Total knee arthroplasty, while elective, should proceed once scheduled unless there are acute medical issues requiring stabilization.
Evidence Quality Context
The 2025 UK consensus 1 represents the most current multidisciplinary guidance specifically addressing GLP-1 perioperative management, endorsed by multiple anesthesia and surgical societies. The 2024 ACC/AHA guideline 2 provides complementary cardiovascular risk stratification principles. Recent meta-analyses 4, 5 involving over 300,000 arthroplasty patients demonstrate that GLP-1 use is associated with reduced infection rates, lower readmissions, and decreased revision rates at 90 days, with no increase in aspiration or pneumonia risk, supporting the safety of continuation.
The key is distinguishing between high-risk patients (new users, dose escalations, symptomatic) who need enhanced precautions versus stable patients who can safely continue therapy with standard aspiration prophylaxis measures.